18 Crosby Drive
About Kaleido BiosciencesKaleido is dedicated to leading a revolution in health. It all starts with the microbiome. In the last ten years, science has revealed the microbiome to be one of the most diverse, powerful organs in the body. At Kaleido, we are pioneering new ways to unlock its power to enable the body to treat disease and heal itself.
CEO and Chairman: Mike Bonney
Co-Founder & President: Geoffrey Von Malzahn, PHD
CMO: Ruth Thieroff-Ekerdt, MD
Senior VP, Research: Jared Silverman, PHD
Senior VP, Finance & Administration: Jeffrey Moore
Senior VP, Corporate Development: Jeremy BUzzard, PHD
President, Food & Nutrition: Michele Fite
Please click here for Kaleido's pipeline.
21 articles with Kaleido Biosciences
11/8/2019Pharmaceutical, medtech and biotech companies expand their leadership teams with this week's appointments.
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced the appointment of William Duke as Chief Financial Officer (CFO), effective November 25, 2019
Kaleido Biosciences, Inc., a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, announced financial results for the third quarter ended September 30, 2019, and provided a corporate update.
Kaleido Biosciences and Washington University School of Medicine to Collaborate on Exploring the Influence of Microbiome Metabolic Therapies (MMT™) on Physiology and Metabolism
Kaleido Biosciences, Inc. has entered into a research collaboration with Jeffrey Gordon, M.D., Director of the Edison Family Center for Genome Sciences and Systems Biology at Washington University School of Medicine, to explore the influence of Microbiome Metabolic Therapies on microbial and host physiology and metabolism.
9/9/2019Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.
A summary of IPOs from companies in the biotech and pharma world since February 1, 2019.
A summary of IPOs from companies in the biotech and pharma world since January 1, 2019.
Despite the government shutdown, at least two biotech companies, Kaleido Biosciences and Cirius Therapeutics, have filed with the U.S. Securities and Exchange Commission (SEC) for initial public offerings (IPO).
Kaleido Biosciences, a healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ, today announced the appointment of three new members to its Board of Directors:
Kaleido Biosciences Announces Appointment of Katharine Knobil, M.D., as Chief Medical Officer and Head of Research & Development
Dr. Knobil joins Kaleido from GlaxoSmithKline (GSK), where she most recently served as CMO
According to BioPharmCatalyst, there have been (or soon will be) 58 biopharma initial public offerings (IPOs) in 2018, and there’s still more than three months to go.
So far in 2018, it’s been a good year for biotech initial public offerings (IPOs). According to a Crunchbase News article, in the second quarter of this year alone, there were at least 16 U.S. venture-backed biotech and healthcare IPOs—compared to only 11 tech IPOs in the same period.
Oversubscribed Financing Includes New and Existing Investors
Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, today announced the appointment of Joshua Brumm as chief financial officer.
Stephen Sofen, Ph.D. to head technical operations and Susan Stewart, J.D. to lead regulatory affairs and quality
Ms. Arnold, who brings more than 20 years of experience in human resources to Kaleido, will report directly to chief executive officer and chair, Michael Bonney.
Kaleido Biosciences Expands Leadership Team with Appointment of Alison Lawton as President and Chief Operating Officer
Ms. Lawton has more than 30 years of experience in a range of executive and operating roles in the biopharmaceutical industry.
Kaleido Biosciences announced today the appointment of John W. Davies, Ph.D. as chief technology officer and Michael D. Bruce, Ph.D. as senior vice president, project, portfolio and alliance management.
Venture capital is hopping, attracted to some of the past several years' successes.